docetaxel,rucaparib,abiraterone,enzalutamide
pfizer,astellas,clovis oncology
['rucaparib', 'prostate', 'brca', 'crpc', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'docetaxel', 'triton3']
dr. alan bryce provides data from the #triton3 trial of #rucaparib vs. docetaxel or second-line anti-androgen for #mcrpc #prostatecancer with #atm or #brca mutations #gu23 
Clinical researcher focused on #ProstateCancer, early recurrence (#BCR)  & #immunotherapy. Views are my own & do not represent the National Cancer Institute